Novel treatments for anal cancer are showing real promise, with the potential to improve survival rates and quality of life. This page explores some of the most promising new treatments, how they work, their status in the UK, and how patients may be able to access them.
Nivolumab
Nivolumab is a drug that helps the immune system destroy cancer cells. It uses immunotherapy, which is a treatment that helps your own immune system recognize and fight diseases like cancer more effectively.
How does it work?
Nivolumab is an immunotherapy drug that belongs to a class known as immune checkpoint inhibitors. These treatments help the immune system recognize and attack cancer cells by blocking proteins that stop immune cells from working properly. In anal cancer, Nivolumab has shown the ability to stimulate the body’s immune defenses to target and destroy cancerous cells, particularly in advanced or metastatic cases.
What is the status of Nivolumab?
In 2017, a study published in The Lancet by researchers at MD Anderson Cancer Center found that Nivolumab produced a response in 24% of patients with metastatic anal cancer. The treatment was also well tolerated with relatively few side effects.
The Anal Cancer Foundation helped co-fund this pivotal research. While not yet standard treatment in the UK, Nivolumab is being studied further in clinical trials and may be an option for patients with advanced or treatment-resistant disease.
Immunotherapies
How does Immunotherapy work?
Immunotherapy works by harnessing the body’s own immune system to fight cancer. Unlike chemotherapy, which attacks all rapidly dividing cells, immunotherapy targets the cancer more selectively, which may reduce some of the unwanted side effects. Types of immunotherapy include checkpoint inhibitors like Nivolumab and other agents that enhance immune response.
What is the status of immunotherapies for anal cancer?
Immunotherapy is a rapidly evolving field, with several new drugs and treatment approaches under investigation for anal cancer. While these therapies are not yet routinely offered for early-stage cases, they may be considered for people with recurrent or advanced disease, or as part of a clinical trial. Ongoing research is looking at combining immunotherapy with chemotherapy or radiation to improve outcomes.
Upcoming Studies
Researchers are now exploring how novel treatments like Nivolumab might work even better when combined with other drugs. Trials are underway to test combinations of immunotherapy agents and traditional treatments, aiming to strengthen their effectiveness. These studies may offer new options for patients whose cancer has returned or hasn’t responded to standard care.
If you think you might be eligible for a clinical trial or would like to explore access to these treatments, we encourage you to contact us for more information. You can also speak to your cancer team or visit ClinicalTrials.gov for a list of ongoing studies.
FAQs
What is targeted therapy, and how does it differ from chemotherapy?
Targeted therapy focuses on specific molecules or pathways involved in cancer growth. Unlike chemotherapy, which affects all fast-growing cells, targeted therapies are designed to block only the processes that cancer cells rely on. This means they may cause fewer side effects and be more effective in certain cases.
Are there any clinical trials available for novel anal cancer treatments?
Yes. Clinical trials are actively exploring new medications, combinations of treatments, and advanced radiotherapy options. Patients can discuss trial eligibility with their oncologist or browse registries like ClinicalTrials.gov.
What is proton beam therapy, and can it be used for anal cancer?
Proton beam therapy is a precise type of radiotherapy that targets tumors with minimal damage to surrounding healthy tissue. While not yet widely used for anal cancer, research is underway to evaluate its benefits, particularly in reducing side effects.
Can novel treatments replace chemotherapy and radiation?
Currently, most novel treatments are used alongside, rather than instead of, standard treatments. However, for those with resistant or recurrent disease, new therapies like immunotherapy may provide alternatives.
What are the potential side effects of novel anal cancer treatments?
Side effects vary depending on the treatment. For immunotherapies like Nivolumab, common effects may include fatigue, rash, nausea, or immune-related reactions. Many patients find these easier to manage than the side effects of chemotherapy or radiation.
Who is eligible for novel treatments for anal cancer?
Eligibility depends on several factors, including the stage of cancer, treatment history, overall health, and whether the cancer has returned or spread. Your oncology team can assess whether a novel treatment or clinical trial is appropriate in your situation.
Want to stay informed?
Sign up for our newsletter to receive updates on the latest research, treatment options, and ways to support the anal cancer community.
Need support or guidance?
Contact us today - we’re here to help.
We're here to empower thrivers and the anal cancer community. But we can't do it without your support.
